**Core Concept**
Brown tumors, compression syndromes, and erythropoietin resistance are manifestations of fibroblast growth factor 23 (FGF-23) mediated bone mineralization defects, typically associated with chronic kidney disease (CKD) and secondary hyperparathyroidism.

**Why the Correct Answer is Right**
In CKD, phosphate retention and secondary hyperparathyroidism lead to increased FGF-23 production. Elevated FGF-23 levels inhibit phosphate reabsorption in the proximal tubules and decrease vitamin D activation, resulting in impaired mineralization of bone. This leads to brown tumors (cystic bone lesions), compression syndromes due to bone deformities, and erythropoietin resistance.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is not relevant to the described clinical scenario.
* **Option B:** While fibroblast growth factor 23 (FGF-23) is indeed involved, this option does not capture the full spectrum of manifestations described.
* **Option D:** This option is a distractor and does not accurately describe the clinical scenario.

**Clinical Pearl / High-Yield Fact**
Remember that brown tumors and compression syndromes are characteristic of advanced CKD, where FGF-23 levels are elevated, and phosphate metabolism is severely disrupted.

**Correct Answer:** C.